BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

6314  relevant articles (510 outcomes, 582 trials/studies) found for this Disease

Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia; Leukemia, Myeloid, Philadelphia Positive; Chronic Granulocytic Leukemia; Leukemia, Chronic Myelogenous; Leukemia, Chronic Myeloid; Myeloid Leukemia, Chronic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelogenous, Ph1 Positive; Leukemia, Myelogenous, Ph1-Positive; Leukemia, Myeloid, Ph1 Positive; Leukemia, Myeloid, Ph1-Positive; Leukemia, Myeloid, Philadelphia-Positive; Myelogenous Leukemia, Ph1-Positive; Myeloid Leukemia, Ph1-Positive; Myeloid Leukemia, Philadelphia-Positive; Chronic Granulocytic Leukemias; Chronic Myelocytic Leukemia; Chronic Myelocytic Leukemias; Chronic Myelogenous Leukemias; Chronic Myeloid Leukemias; Granulocytic Leukemias, Chronic; Leukemia, Chronic Granulocytic; Leukemia, Chronic Myelocytic; Leukemia, Ph1-Positive Myelogenous; Leukemia, Ph1-Positive Myeloid; Leukemia, Philadelphia-Positive Myeloid; Leukemias, Chronic Granulocytic; Leukemias, Chronic Myelocytic; Leukemias, Chronic Myelogenous; Leukemias, Chronic Myeloid; Leukemias, Ph1-Positive Myelogenous; Leukemias, Ph1-Positive Myeloid; Leukemias, Philadelphia-Positive Myeloid; Myelocytic Leukemias, Chronic; Myelogenous Leukemia, Ph1 Positive; Myelogenous Leukemias, Chronic; Myelogenous Leukemias, Ph1-Positive; Myeloid Leukemia, Ph1 Positive; Myeloid Leukemia, Philadelphia Positive; Myeloid Leukemias, Chronic; Myeloid Leukemias, Ph1-Positive; Myeloid Leukemias, Philadelphia-Positive; Ph1-Positive Myelogenous Leukemia; Ph1-Positive Myelogenous Leukemias; Ph1-Positive Myeloid Leukemia; Ph1-Positive Myeloid Leukemias; Philadelphia-Positive Myeloid Leukemia; Philadelphia-Positive Myeloid Leukemias; Granulocytic Leukemia, Chronic; Leukemia, Granulocytic, Chronic; Leukemia, Myelocytic, Chronic; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Chronic; Myelocytic Leukemia, Chronic; Myelogenous Leukemia, Chronic

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Leukemia
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
4.	Blast Crisis (Blast Phase)
5.	Philadelphia Chromosome

Experts

1.	Cortes, Jorge: 72 articles (09/2008 - 03/2002)
2.	Kantarjian, Hagop: 60 articles (09/2008 - 02/2002)
3.	Talpaz, Moshe: 52 articles (04/2008 - 02/2002)
4.	O'Brien, Susan: 48 articles (08/2008 - 05/2002)
5.	Giles, Francis: 39 articles (02/2008 - 01/2003)
6.	Garcia-Manero, Guillermo: 38 articles (09/2008 - 05/2002)
7.	Faderl, Stefan: 32 articles (09/2008 - 05/2002)
8.	Kantarjian, Hagop M: 32 articles (07/2008 - 03/2002)
9.	Rios, Mary Beth: 30 articles (10/2007 - 05/2002)
10.	Verstovsek, Srdan: 28 articles (10/2007 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to BCR-ABL Positive Chronic Myelogenous Leukemia:

1.	imatinib (Gleevec)FDA Link 04/01/2008 - "Imatinib has dramatically altered the natural history of chronic myelogenous leukemia (CML), with the majority of patients now experiencing long-term remission and improved survival" 02/15/2008 - "Imatinib mesylate (imatinib) is highly effective in the treatment of chronic myeloid leukemia (CML) but is less effective in eliminating CML stem cells" 11/01/2007 - "BACKGROUND: Although imatinib is highly effective in chronic myeloid leukemia (CML), drug-resistance may occur" 01/01/2007 - "Most patients with a chronic phase of chronic myeloid leukemia (CML) treated with imatinib mesylate achieve a cytogenetic remission, but in the majority, residual disease is detectable by RT-PCR" 05/15/2006 - "PURPOSE: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts" Order ALL the reference details at left...
2.	Interferon-alpha (Interferon Alfa)FDA Link 01/01/2004 - "In June 2002, he was diagnosed as having the chronic phase of chronic myelogenous leukemia (CML), and following treatment with interferon-alpha, he achieved hematological complete remission" 01/01/2002 - "Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa." 04/01/1998 - "PURPOSE: Interferon alfa (IFN-alpha) induces complete cytogenetic remission in a significant minority of patients with chronic myelogenous leukemia (CML)" 09/06/1997 - "Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment]" 12/01/1994 - "Interferon-alpha has been used for chronic myeloid leukemia patients and may achieve hematological and cytogenetic complete remission" Order ALL the reference details at left...
3.	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/01/2000 - "Tyrosine kinase inhibitors: a cure for chronic myeloid leukemia?" 08/01/2004 - "In a previous study, we reported that protein tyrosine kinase (PTK) inhibitors modulate the radiation responses in the human chronic myelogenous leukemia (CML) cell line K562" 02/01/2002 - "OBJECTIVE: To study the effects of anti-ABL tyrosine kinase intrabody on the growth of human chronic myelogenous leukemia (CML) cells in nude mice" 07/01/2001 - "Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors." 12/01/1996 - "Recent studies of the BCR-ABL fusion protein, the product of the oncogene responsible for chronic myelogenous leukemia, have identified a number of signal transduction pathways that are activated by this tyrosine kinase" Order ALL the reference details at left...
4.	InterferonsIBA 11/01/1998 - "Interferon (IFN)-alpha may induce hematological remission in chronic myeloid leukemia (CML) patients, but only a small proportion of patients achieve a sustained, complete cytogenetic remission" 07/01/1996 - "Additional translocation (9;12)(p13;q24.1) in newly diagnosed chronic myeloid leukemia: complete cytogenetic remission after interferon therapy." 02/15/1992 - "Interferon (IFN) therapy of early chronic myelogenous leukemia (CML) frequently produces partial or complete cytogenetic remission of the disease" 06/01/2000 - "Interferon (IFN) is an effective treatment for chronic myeloid leukemia (CML) in chronic phases, and a number of in vitro antileukemic effects of IFN on CML cells have been reported" 09/01/1992 - "Clonogenic assay is not predictive but reflects therapeutic efficacy of interferons in the treatment of chronic myelogenous leukemia." Order ALL the reference details at left...
5.	Busulfan (Busulfex)FDA Link 02/01/1989 - "Appearance of chromosomally normal hemopoiesis during busulfan-induced remission in a case of Ph1 positive chronic myelogenous leukemia]" 01/01/1985 - "Survival in 73 patients with Ph1-positive chronic myelocytic leukemia was correlated with remission duration and leukocyte doubling time after initial treatment with busulfan and also, with clinical and laboratory features recorded at the time of diagnosis" 01/01/1978 - "A patient with chronic myelocytic leukemia in whom a clinical and hematological remission occurred after a single course of busulfan is described" 01/01/1978 - "A 13-years remission in chronic myelocytic leukemia after a single course of busulfan." 01/01/1966 - "Prolonged remission in chronic myeloid leukemia after one course of busulfan." Order ALL the reference details at left...
6.	Phosphotransferases (Kinase)IBA 10/01/2007 - "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia." 01/01/2005 - "Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek]" 11/01/2006 - "Most studies test for mutations in the kinase domain of the abl gene in chronic myeloid leukemia (CML) using peripheral blood (PB) cells" 05/15/1994 - "In the current study, we show that CRKL is highly phosphorylated in the chronic myelogenous leukemia cell line K562 and that it is a substrate for the p210 BCR/ABL and p145 ABL kinases" 06/27/2008 - "ABL kinase is an important drug target in the treatment of chronic myelogenous leukemia" Order ALL the reference details at left...
7.	Bcr-Abl tyrosine kinaseIBA 04/01/2008 - "In chronic myeloid leukemia (CML), neoplastic stem cells and/or their subclones exhibit resistance against BCR/ABL tyrosine kinase inhibitors (TKIs)" 03/01/2008 - "BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices." 02/15/2008 - "Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods." 07/19/2007 - "BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia." 02/01/2007 - "BACKGROUND: The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML)" Order ALL the reference details at left...
8.	Cytarabine (Cytosar-U)FDA LinkGeneric 02/01/2007 - "A prospective randomized phase III study was performed to evaluate whether intensified cytarabine would induce a higher response rate and longer event-free interval as compared to low-dose cytarabine in chronic myeloid leukemia (CML)" 06/01/2000 - "In the in vitro part of our study, normal granulocyte-macrophage colony-forming unit (CFU-GM) cells as well as CFU-GM cells obtained from patients with chronic myeloid leukemia (CML) were incubated either with dFdC or Ara-C alone or with adequate concentrations of a combination of these drugs" 01/01/1988 - "On the basis of in-vitro studies indicating that low concentrations of cytosine arabinoside exert preferential inhibition of granulocyte-macrophage colony-forming cells from patients with chronic granulocytic leukemia vs normal subjects, we treated two outpatients with low doses of this agent, administered by subcutaneous infusion for 12-31 days" 09/01/2005 - "Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia." 02/01/2005 - "Human chronic myelogenous leukemia K562 cells are relatively resistant to the anti-metabolite cytosine arabinoside (Ara-C) and, when treated with Ara-C, they differentiate into erythrocytes without undergoing apoptosis" Order ALL the reference details at left...
9.	Cyclophosphamide (Cytoxan)FDA Link 08/01/1994 - "We studied 15 variables in 46 patients with chronic myeloid leukemia (CML) treated with cyclophosphamide, total body irradiation (TBI) and allogeneic BMT" 07/01/1994 - "High-dose cyclophosphamide for mobilization of circulating stem cells in chronic myeloid leukemia." 02/01/1992 - "We performed allogeneic BMT in 32 patients with chronic granulocytic leukemia by using unmanipulated donor marrow and a conditioning regimen that consisted of cyclophosphamide and total-body irradiation" 10/01/1986 - "The in vitro cytotoxicity and mechanism of action of cyclophosphamide (CP) were studied in a dual cell culture system, using rat hepatocytes and K562 human chronic myeloid leukemia cells" 09/01/1985 - "Forty-eight patients with chronic myelocytic leukemia, aged 11 to 47, were treated with high-dose cyclophosphamide and fractionated total body irradiation, followed by infusion of marrow from HLA-identical siblings" Order ALL the reference details at left...
10.	Messenger RNA (mRNA)IBA 08/01/1998 - "Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection?" 08/01/2008 - "The purpose of this study was to investigate the growth characteristics and the expression level of integrin mRNA of the cultured bone marrow mesenchymal stem cells (BMMSCs) from patients with chronic myeloid leukemia (CML) in myeloid crisis (MC), and explore the role of BMMSCs in pathogenesis of CML" 01/01/2008 - "The technique has been utilised to study 12 patients with chronic myeloid leukemia, and the results were compared with those of BCR-ABL fusion mRNA by RT-PCR and BCR-ABL fusion gene of the interphase cells by fluorescence in situ hybridization (FISH)" 07/01/2005 - "In this study, we report the case of a Philadelphia (Ph) positive chronic myelogenous leukemia (CML) patient with the presence of p190 and p210 BCR-ABL1 mRNA fusion transcripts derived from e1a2 and b3a2 BCR-ABL1 genomic rearrangements, respectively" 12/01/1993 - "Leukemic cells from two patients with Philadelphia-negative chronic myeloid leukemia (CML) were investigated: 1) Cytogenetics showed a normal 46,XY karyotype in both cases, 2) molecular studies revealed rearrangement of the M-BCR region and formation of BCR-ABL fusion mRNA with b2a2 (patient 1) or b3a2 (patient 2) configuration, and 3) fluorescence in situ hybridization (FISH) demonstrated relocation of the 5' BCR sequences from one chromosome 22 to one chromosome 9. The ABL probe hybridized to both chromosomes 9 at band q34, while two other probes which map centromeric and telomeric of BCR on 22q11 hybridized solely with chromosome 22" Order ALL the reference details at left...

Therapies and Procedures

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 06/01/2000 - "BACKGROUND AND OBJECTIVE: For purposes of therapeutic decision making, we used quantitative polymerase chain reaction (PCR) for molecular follow-up of 55 patients with chronic myeloid leukemia (CML) in complete remission (CR) after allogeneic bone marrow transplantation (BMT) from HLA compatible donors" 02/01/1999 - "PURPOSE: Donor lymphocyte infusion (DLI) can restore complete remission in patients with chronic myelogenous leukemia (CML) who have relapsed after T-cell-depleted (TCD) allogeneic bone marrow transplantation (BMT)" 11/01/1998 - "Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT)" 03/01/1998 - "The authors report the case of a chronic myeloid leukemia (CML) patient submitted to allogenic bone marrow transplantation, who had probably never entered complete remission" 12/01/1995 - "Donor lymphocyte infusions can reinduce complete remission in the majority of patients with chronic myelogenous leukemia (CML) who relapse into chronic phase after allogeneic bone marrow transplantation (BMT)" Order ALL the reference details at left...
2.	Transplants (Transplant) 10/01/1999 - "The infusion of lymphocytes from the original marrow donor (donor lymphocyte infusion [DLI]) reinduces complete remission in a high percentage of patients with chronic myeloid leukemia (CML) who relapse after allogeneic stem cell transplant, and thus, is probably the best initial approach to their management" 01/01/2002 - "For patients who relapse with chronic myelogenous leukemia after matched sibling SCT, infusions of leukocytes collected from the original transplant donor will re-establish complete and durable remission in 60-80% of patients" 09/01/2000 - "In the case of chronic myelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-alpha2b (IFN-alpha2b) therapy can result in complete remission, but the mechanism for prolonged disease control is unknown and may involve immune anti-leukemic responses" 06/01/1992 - "Forty-eight long-term disease-free chronic myelogenous leukemia (CML) patients, who had received unmanipulated allogeneic bone marrow transplants (BMT) for eradication of the Philadelphia (Ph1)-positive clone were studied by polymerase chain reaction (PCR), using a very sensitive PCR procedure and very stringent criteria for preventing and revealing contamination" 04/02/1998 - "We analyzed the safety and efficacy of transplants from unrelated donors for the treatment of chronic myeloid leukemia and identified variables that predict a favorable outcome" Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 03/01/1997 - "It was very effective in the treatment of chronic myelogenous leukemia recurring after marrow transplantation" 01/01/2004 - "CONCLUSION: The experience of many years demonstrates high efficacy of ABM transplantation in the treatment of chronic myeloid leukemia" 10/01/1995 - "bcr/abl chimeric transcript in patients in remission after marrow transplantation for chronic myeloid leukemia: higher frequency of detection and slower clearance in patients grafted in advanced disease as compared to patients grafted in chronic phase." 03/01/2007 - "OBJECTIVE: To monitor the gene expression of BCR/ABL in chronic myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation with real-time RT-PCR for evaluating therapeutic efficacy and guiding further treatment" 04/02/1998 - "CONCLUSIONS: Transplantation of marrow from an HLA-matched, unrelated donor is safe and effective therapy for selected patients with chronic myeloid leukemia." Order ALL the reference details at left...
4.	Drug Therapy (Chemotherapy) 04/01/2003 - "chronic phase of chronic myeloid leukemia (CML) or complete remission of other disease post chemotherapy (n=24), (4)" 05/01/1994 - "Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy" 07/01/1993 - "Chronic myelogenous leukemia: progress in chemotherapy and evaluation of prognostic score 1. The German CML Study Group." 10/01/1990 - "In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion" 10/01/1990 - "Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion." Order ALL the reference details at left...
5.	Stem Cell Transplantation 03/01/2004 - "Donor lymphocyte infusion (DLI) results in complete cytogenetic remission (CCR) of relapsed chronic-phase chronic myeloid leukemia (CML-CP) after allogeneic stem cell transplantation (SCT) in up to 80% of patients" 05/15/2002 - "Donor lymphocyte infusion (DLI) can restore durable molecular remission in a high percentage of patients with chronic myeloid leukemia (CML) who have relapses after allogeneic stem cell transplantation, but for patients who do not respond survival is poor" 12/01/2005 - "Donor lymphocyte infusions (DLI) have been the mainstay of treatment for chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (allo-SCT)" 11/01/1999 - "The infusion of lymphocytes from the original marrow donor (donor lymphocyte infusions [DLI]) is remarkably effective in treating chronic myeloid leukemia in relapse after allogeneic stem cell transplantation" 08/18/1998 - "Adoptive immunotherapy with donor lymphocyte infusions (DLI) is an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation" Order ALL the reference details at left...